{"action":[{"action":[{"action":[{"action":[{"action":[{"definitionCanonical":"#1111","extension":[{"extension":[{"url":"day","valueInteger":1},{"url":"day","valueInteger":8}],"url":"http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle"}],"id":"action-1","textEquivalent":"Gemcitabine 1250 mg/m² IV over 30 minutes on days 1 and 8"},{"definitionCanonical":"#2222","extension":[{"extension":[{"url":"day","valueInteger":1}],"url":"http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle"}],"id":"action-2","relatedAction":[{"relationship":"concurrent-with-start","targetId":"action-1"}],"textEquivalent":"CARBOplatin AUC 5 IV over 30 minutes on Day 1"}],"id":"cycle-definition-1","textEquivalent":"21-day cycle for 6 cycles","timingTiming":{"repeat":{"count":6,"duration":21,"durationUnit":"d"}}}],"groupingBehavior":"sentence-group","selectionBehavior":"exactly-one"}],"selectionBehavior":"all"}],"selectionBehavior":"exactly-one"}],"approvalDate":"2016-07-27","author":[{"name":"Lee Surprenant"}],"contact":[{"telecom":[{"system":"url","value":"http://www.hl7.org/Special/committees/dss"}]}],"contained":[{"dosage":[{"doseAndRate":[{"doseQuantity":{"unit":"mg/m²","value":1250},"type":{"coding":[{"code":"ordered","display":"Ordered","system":"http://terminology.hl7.org/CodeSystem/dose-rate-type"}]}}],"route":{"text":"IV"},"text":"1250 mg/m² IV over 30 minutes","timing":{"repeat":{"duration":30,"durationUnit":"min"}}}],"id":"1111","productCodeableConcept":{"coding":[{"code":"12574","display":"gemcitabine","system":"http://www.nlm.nih.gov/research/umls/rxnorm"}],"text":"gemcitabine"},"resourceType":"ActivityDefinition","status":"draft"},{"dosage":[{"doseAndRate":[{"doseQuantity":{"extension":[{"url":"http://example.org/fhir/AUC-dose","valueInteger":5}]},"type":{"coding":[{"code":"ordered","display":"Ordered","system":"http://terminology.hl7.org/CodeSystem/dose-rate-type"}]}}],"route":{"text":"IV"},"text":"AUC 5 IV over 30 minutes","timing":{"repeat":{"duration":30,"durationUnit":"min"}}}],"id":"2222","productCodeableConcept":{"coding":[{"code":"40048","display":"Carboplatin","system":"http://www.nlm.nih.gov/research/umls/rxnorm"}],"text":"CARBOplatin"},"resourceType":"ActivityDefinition","status":"draft"}],"copyright":"All rights reserved.","description":"Gemcitabine/CARBOplatin","experimental":true,"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"cds"}],"id":"KDN5","identifier":[{"system":"http://example.org/ordertemplates","value":"KDN5"},{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.4.642.11.21"}],"lastReviewDate":"2016-07-27","name":"GemcitabineCARBOplatin","publisher":"HL7 International / Clinical Decision Support","relatedArtifact":[{"display":"NCCN Guidelines for Kidney Cancer. V.2.2016","document":{"url":"http://www.example.org/professionals/physician_gls/PDF/kidney.pdf"},"type":"derived-from"},{"_type":{"extension":[{"url":"http://example.org/fhir/regimenReferenceType","valueCode":"a"}]},"citation":"Oudard S, et al. J Urol. 2007;177(5):1698-702","document":{"url":"http://www.ncbi.nlm.nih.gov/pubmed/17437788"},"type":"citation"}],"resourceType":"PlanDefinition","status":"draft","text":{"div":"
\n \n \n \n \n \n \n
\n
National Comprehensive Cancer Network
\n 		\n

Chemotherapy Order Template

\n

Kidney Cancer

\n

Gemcitabine/CARBOplatin

\n 		KDN5
\n \n \n \n \n \n \n
\n

INDICATION:

\n

Metastatic or Relapsed – Collecting Duct/Medullary Subtypes

\n 		\n

REFERENCES:

\n
    \n
  1. \n NCCN Guidelines® for Kidney Cancer. V.3.2015.\n
    2. \n
  2. \n Oudard S, et al. \n J Urol. 2007;177(5):1698-702.\n \n \n a\n \n
    3. \n
\n 		\n

NCCN SUPPORTIVE CARE:

\n
    \n
  1. \n Emetic Risk:\n \n \n \n \n \n \n \n \n \n
    Day 1Moderate
    Day 8Low
    \n
    2. \n
  2. \n Fever Neutropenia Risk:\n
    \n Refer to \n NCCN Guidelines for Myeloid Growth Factors. V.2.2014\n
    3. \n
\n
\n

CHEMOTHERAPY REGIMEN

\n

\n 21-day cycle for 6 cycles\n

\n \n
","status":"additional"},"title":"Gemcitabine/CARBOplatin","type":{"text":"Chemotherapy Order Template"},"useContext":[{"code":{"code":"treamentSetting-or-diseaseStatus","system":"http://example.org/fhir/CodeSystem/indications"},"valueCodeableConcept":{"text":"Metastatic"}},{"code":{"code":"disease-or-histology","system":"http://example.org/fhir/CodeSystem/indications"},"valueCodeableConcept":{"text":"Collecting Duct/Medullary Subtypes"}},{"code":{"code":"focus","system":"http://terminology.hl7.org/CodeSystem/usage-context-type"},"valueCodeableConcept":{"text":"Kidney Cancer"}},{"code":{"code":"treatmentSetting-or-diseaseStatus","system":"http://example.org/fhir/CodeSystem/indications"},"valueCodeableConcept":{"text":"Relapsed"}},{"code":{"code":"disease-or-histology","system":"http://example.org/fhir/CodeSystem/indications"},"valueCodeableConcept":{"text":"Collecting Duct/Medullary Subtypes"}},{"code":{"code":"focus","system":"http://terminology.hl7.org/CodeSystem/usage-context-type"},"valueCodeableConcept":{"text":"Kidney Cancer – Collecting Duct/Medullary Subtypes - Metastatic"}}],"version":"1"}